Drug Profile
NN 2501
Latest Information Update: 07 Jul 2006
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2005 Discontinued - Phase-I for Type-2 diabetes mellitus in Denmark (PO)
- 21 Feb 2003 Phase-I clinical trials in Type-2 diabetes mellitus in Denmark (PO)